spironolactone has been researched along with Acute Coronary Syndrome in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary syndromes in patients with systolic HF and mild symptoms." | 9.20 | Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. ( Collier, T; Girerd, N; Krum, H; McMurray, JJ; Pitt, B; Pocock, S; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F, 2015) |
| "Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary syndromes in patients with systolic HF and mild symptoms." | 5.20 | Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. ( Collier, T; Girerd, N; Krum, H; McMurray, JJ; Pitt, B; Pocock, S; Swedberg, K; Van Veldhuisen, DJ; Vincent, J; Zannad, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maggioni, AP | 1 |
| Girerd, N | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Krum, H | 1 |
| McMurray, JJ | 1 |
| Swedberg, K | 1 |
| Van Veldhuisen, DJ | 1 |
| Vincent, J | 1 |
| Pitt, B | 1 |
| Zannad, F | 1 |
1 trial available for spironolactone and Acute Coronary Syndrome
| Article | Year |
|---|---|
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Topics: Acute Coronary Syndrome; Aged; Eplerenone; Female; Follow-Up Studies; Heart Failure, Systolic; Hospi | 2015 |
1 other study available for spironolactone and Acute Coronary Syndrome
| Article | Year |
|---|---|
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |